about
Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen in vitro and in vivo?Current characteristics and outcome of cytomegalovirus infections after kidney transplantation.Novel GMP-compatible protocol employing an allogeneic B cell bank for clonal expansion of allospecific natural regulatory T cells.Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial.Deficient EBV-specific B- and T-cell response in patients with chronic fatigue syndrome.Can we use biomarkers and functional assays to implement personalized therapies in transplantation?Lymphocyte markers and prediction of long-term renal allograft acceptance.Pretransplant immune risk assessment.Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.BK polyomavirus infection and nephropathy: the virus-immune system interplay.Monitoring tolerance and rejection in organ transplant recipients.A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV.Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.Generation of a human induced pluripotent stem cell line from urinary cells of a healthy donor using integration free Sendai virus technology.Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.Generation of a human induced pluripotent stem cell line from urinary cells of a healthy donor using an integration free vector.WITHDRAWN: Generation of a human induced pluripotent stem cell line from urinary cells of a healthy donor using integration free Sendai technology.Overcoming Challenges Facing Advanced Therapies in the EU Market.Comparative characterization of decellularized renal scaffolds for tissue engineering.Immunization of liver and renal transplant recipients: a seroepidemiological and sociodemographic survey.Gene therapy: a possible future standard for HIV care.Prophylaxis of recurrent urinary tract infection after renal transplantation by cranberry juice and L-methionine.Simultaneous pancreas/kidney transplant recipients are predisposed to tissue-invasive cytomegalovirus disease and concomitant infectious complications.Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.Diabetic kidney transplant recipients: Impaired infection control and increased alloreactivity.Sepsis after renal transplantation: Clinical, immunological, and microbiological risk factors.Generation of integration free induced pluripotent stem cells from fibrodysplasia ossificans progressiva (FOP) patients from urine samples.To be, or not to be immunocompetent.Mesenchymal Stromal Cells Prevent Allostimulation In Vivo and Control Checkpoints of Th1 Priming: Migration of Human DC to Lymph Nodes and NK Cell Activation.Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency.Comparing Humoral and Cellular Immune Response Against HBV Vaccine in Kidney Transplant Patients.The Loss of BKV-specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication.The role of CD4(+) T cells in BKV-specific T cell immunity.Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients.TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology.Expansion of memory-type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and rapamycin.Accelerating Patients' Access to Advanced Therapies in the EU.Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock.Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients.
P50
Q28084829-79D7068C-6928-4AE0-84CE-69D166109BD4Q33416126-ECA9EB14-6259-4A4D-ACF9-575279C3AC21Q33456264-C43A1ADE-79B1-4816-8780-0A3868C0BF4EQ36248860-F53A3120-998D-43FD-80D1-9511292E8E16Q37484088-242B697C-3F25-492B-A79E-02CC5C28397EQ37510489-ABF34392-37B1-4B4A-89A4-47A19CF1D42BQ37590628-B6FC3991-30ED-4340-BE61-1EE86CAF24FBQ37603035-1BC47B85-62F0-4370-8DD4-6DEB493A53A9Q37704588-5BA6F82F-BEFF-4CFD-B9B5-3FF6900C057EQ37879442-DA46E5AC-0009-4E87-BD09-94CB1C1A4636Q37894733-4ABE0F5D-47AE-4442-93C0-74A0D1C198FBQ38254933-21EB2A5D-244B-4ABF-B158-8E55090E4C1EQ38383351-BC65503B-A64A-47DD-8E7D-7F84AC451A7AQ38698106-56FD509E-C26E-4B27-BD9B-49E56C304BD0Q38726059-C7A857F9-18B7-4A7D-AAAE-4279EB134846Q38761959-84E7BD79-EA19-4CAB-AF58-D2F82D761685Q38762076-55779CAE-7DFF-4B2F-98A6-4602A440911DQ38824969-1FB7CF62-7110-4805-B7C3-B360CBBC3F0AQ38843480-9CB4C8C5-F471-4321-B7F0-16C00F743448Q38943572-C7C304F1-BC90-48B8-BA22-C28466E19248Q38994148-0EC30929-154F-40EB-8D76-545051CAC58BQ39237303-565707AD-BDA0-44B5-8A43-9D9D507213AEQ40139857-3284AD71-B53A-471F-ABBE-49443E4C8F4EQ40176051-387C07AB-9319-4589-861A-D8BA3B71423AQ40183378-6A192F1F-6F87-4637-AEE7-B48C7616BC25Q40245332-1B28F91A-4728-45E2-A188-F12B154CFF9BQ40293393-7B48483D-BE45-4DD9-8E5B-B29CF4746640Q40681289-6F261486-9514-40FE-BB1F-874900EE08D0Q40699920-5364DF67-05BA-45CC-B0CF-7794B2ABC619Q40726535-4CA02CF0-854A-4083-BD71-58CCA042138AQ41008417-F636C611-F740-4E9B-A088-AD92FFD848B3Q41126510-511B4E92-84CA-4ACF-8F78-7D88AE67FF0CQ41385328-67842E0D-7958-4706-99E9-9DCB8B8452DFQ42204515-8906D16B-A9A0-4C41-94C1-A1985D42EDF1Q42242062-207A3266-5F6C-4238-8193-949CB7B0C273Q42270935-1C1C656C-3CC6-4F72-89E5-24152B8C464FQ42288307-BFB782FE-E388-4F65-9A16-D9437909F76FQ42362633-3CFF6531-63DE-4B4A-8559-AA4C93C6C664Q43230804-3CFC1999-4637-4495-B21C-0EA2B6052EFBQ43257553-2666BA2A-7C40-4370-95C7-23AE744172B3
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Petra Reinke
@en
Petra Reinke
@nl
type
label
Petra Reinke
@en
Petra Reinke
@nl
prefLabel
Petra Reinke
@en
Petra Reinke
@nl
P31
P496
0000-0003-0771-4375